文献速递类风湿关节炎

英夫利西单抗治疗的类风湿关节炎患者体重指数与疾病活动度变化及影像学进展的纵向关联

Longitudinal associations between body mass index and changes in disease activity and radiographic progression in rheumatoid arthritis patients treated with infliximab.
PubMed 文献 · RMD Open · 2023-01-01

在瑞士风湿病临床质量管理注册库(1997-2020)中纳入英夫利西单抗使用者,评估体重指数(BMI)与类风湿关节炎疾病活动度(DAS28-esr)变化及影像学进展(Rau评分)的纵向关联。队列1(412例)中BMI升高与平均DAS28-esr变化无关联(校正系数0.00,95%CI -0.02至0.02);队列2(187例)中BMI每增加1个单位,平均Rau评分显著下降1.05(校正系数-1.05,95%CI -1.92至-0.19)。

要点

  • 英夫利西单抗治疗患者中BMI升高与DAS28-esr变化无显著关联(校正系数0.00,95%CI -0.02至0.02)。
  • BMI每增加1个单位,平均Rau评分显著下降1.05(校正系数-1.05,95%CI -1.92至-0.19)。
  • 按BMI分类分层后,结果在各类别中均未达统计学显著。

核心结论

  • 纵向研究提示,接受英夫利西单抗治疗的患者中BMI增加可能不导致DAS28-esr变化,尽管剂量按体重调整。
  • BMI增加可能与侵蚀减少相关,且不限于肥胖患者。

研究设计与样本

  • 研究基于瑞士风湿病临床质量管理注册库(1997-2020),纳入确诊类风湿关节炎且使用英夫利西单抗的患者。
  • 队列1从首次BMI测量或DAS28-esr评估开始,共412例(74%女性,平均年龄53岁,平均BMI 25)。
  • 队列2从首次BMI测量或影像学评估(Rau评分)开始,共187例,与队列1特征高度相似。
  • 采用广义估计方程评估BMI与平均DAS28-esr变化(队列1)及平均Rau评分变化(队列2)的系数及95%CI,并总体及按BMI分类分层分析。

主要发现

  • 队列1中,BMI升高与平均DAS28-esr变化总体无关联(校正系数0.00,95%CI -0.02至0.02),按BMI分类分层亦无关联。
  • 队列2中,BMI每增加1个单位,平均Rau评分显著下降1.05(校正系数-1.05,95%CI -1.92至-0.19)。
  • 按BMI分类分层后,结果均未达统计学显著。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Treatment response is worse in obese patients with rheumatoid arthritis (RA), including patients on weight-adjusted therapies like infliximab. We aimed to assess the association between body mass index (BMI) and changes in RA disease activity and radiographic progression over time. METHODS: We included infliximab users with an RA diagnosis in the Swiss Clinical Quality Management in Rheumatic Diseases registry (1997-2020). Two cohorts were defined: (1) starting from their first BMI measurement or disease activity score (DAS28-esr), and (2) from their first BMI measurement or radiographic assessment (Rau score). We evaluated the coefficient and 95% CI of BMI with changes in mean DAS28-esr (cohort 1) and mean Rau scores (a structural joint damage score, cohort 2) using generalised estimation equations, overall and stratified by BMI categories. RESULTS: Cohort 1 comprised 412 patients (74% women, mean age 53 years, mean BMI 25). We observed no change in mean DAS28-esr with increasing BMI overall (adjusted coefficient: 0.00, 95% CI -0.02 to 0.02), or in BMI categories. Cohort 2 comprised 187 patients highly alike to those in cohort 1. We observed a significant decrease of 1.05 in mean Rau scores for every increase in BMI unit (adjusted coefficient: -1.05, 95% CI -1.92 to -0.19). Results remained statistically non-significant across BMI categories. CONCLUSIONS: Our longitudinal investigation suggests that BMI increase may not lead to changes in DAS28-esr in patients receiving infliximab, despite the weight-adapted dose. Yet, there may be a decrease in erosions with increasing weight non-limited to obese patients.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Burkard T, Vallejo-Yagüe E, Lauper K, et al. Longitudinal associations between body mass index and changes in disease activity and radiographic progression in rheumatoid arthritis patients treated with infliximab. RMD Open. 2023. PMID: 37802600. doi:10.1136/rmdopen-2023-003396

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。